Experimental drug combo aims to tame bone marrow cancer
NCT ID NCT05371964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests two drugs—imetelstat and ruxolitinib—together in people with myelofibrosis, a type of bone marrow cancer. The study has two parts: first, finding a safe dose of the combination, and second, checking if it improves symptoms like fatigue and spleen discomfort. About 36 adults with intermediate or high-risk myelofibrosis are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imetelstat and ruxolitinib
What this could lead to
If it works, this combination could offer better symptom control and possibly slow disease progression for people with myelofibrosis.
What could go wrong
This is an early Phase 1 trial with only 36 participants, so safety and effectiveness are not yet proven. Side effects from the drug combination are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
City of Hope
RECRUITINGIrvine, California, 92618, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
H. Lee Moffitt Cancer Center and Research Institute, Inc.
RECRUITINGTampa, Florida, 33612, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Texas Oncology
WITHDRAWNDenison, Texas, 75020, United States
-
Texas Oncology
WITHDRAWNTyler, Texas, 75702, United States
-
University of Miami
RECRUITINGCoral Gables, Florida, 33146, United States